LoginSignup
BioCryst Pharms logo

BioCryst Pharms Stock

StockStock
ISIN: US09058V1035
Ticker: BCRX
US09058V1035
BCRX

Price

Frequently asked questions

What is BioCryst Pharms's market capitalization?

The market capitalization of BioCryst Pharms is $1.70B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for BioCryst Pharms?

BioCryst Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.607. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for BioCryst Pharms's stock?

Currently, 12 analysts cover BioCryst Pharms's stock, with a consensus target price of $14.00. Analyst ratings provide insights into the stock's expected performance.

What is BioCryst Pharms's revenue over the trailing twelve months?

Over the trailing twelve months, BioCryst Pharms reported a revenue of $412.58M.

What is the EBITDA for BioCryst Pharms?

BioCryst Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$39.00M. EBITDA measures the company's overall financial performance.

What is the free cash flow of BioCryst Pharms?

BioCryst Pharms has a free cash flow of -$56.73M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of BioCryst Pharms's stock?

The 5-year beta for BioCryst Pharms is 1.82. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does BioCryst Pharms have, and what sector and industry does it belong to?

BioCryst Pharms employs approximately 536 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of BioCryst Pharms's shares?

The free float of BioCryst Pharms is 200.91M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $1.70B

5Y beta

 1.82

EPS (TTM)

 -$0.607

Free Float

 200.91M

Revenue (TTM)

 $412.58M

EBITDA (TTM)

 -$39.00M

Free Cashflow (TTM)

 -$56.73M

Pricing

1D span
$7.722$8.241
52W span
$4.03$8.88

Analyst Ratings

The price target is $14.00 and the stock is covered by 12 analysts.

Buy

9

Hold

3

Sell

0

Information

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

536

Biotechnology & Drugs

Health Care

Identifier

ISIN

US09058V1035

Primary Ticker

BCRX

Knockouts

Join the conversation
Sign upLogin